Clinical trials: Substance Addiction
Nicotine Dependence
Multimodal Neuroimaging Genetic Biomarkers of Nicotine AddictionSeverity
Background: Smoking is a difficult habit to quit, and some people find it more difficult to quit than others do. Nicotine is the substance in cigarettes that makes smoking so addictive.
- Trial name
- NCT01867411
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Tobacco Use Disorder, Nicotine Dependence, Cigarettes
Effects of Nicotine Dependence on Multidimensional Health Outcomes
Nicotine, a major toxic component of cigarette smoke, together with carbon monoxide (CO), constitutes a significant environmental exposure with systemic effects.
- Trial name
- NCT07474623
- Testing
- Comprehensive Clinical Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Izmir Democracy University
Nicotine Addiction, Panic Attack
Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine
The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks.
- Trial name
- DCS/PSRT (NCT01944423)
- Testing
- d-cycloserine, Nicotine replacement therapy, Panic and Smoking Reduction Treatment
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Smoking Cessation
Interventions for Smoking Among Persons in Recovery
Examine the efficacy of a stepped-care smoking cessation intervention for current and former smokers in chemical dependency treatment programs.
- Trial name
- INSPIRE (NCT00714896)
- Testing
- Stepped-Care, Control
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Alcohol Dependence, PTSD
Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence
The purpose of this study is to examine the effect of propranolol versus placebo on craving, distress and cue reactivity to trauma and alcohol cues.
- Trial name
- NCT01055171
- Testing
- Propranolol
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Nicotine Dependence, Nicotine Addiction
Effectiveness of N-Acetylcysteine (NAC) in Motivational Enhancement Therapy for Nicotine Addiction
The goal of this clinical trial is to determine the effectiveness of the combination of n-acetylcysteine and motivational enhancement therapy on laboratory improvement in the form of changes in blood nicotine, radiological…
- Trial name
- NCT05903014
- Testing
- n-acetylcysteine, Motivational Enhancement Therapy
- Where
- Indonesia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Nicotine Addiction, Drug Addiction
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
This study is evaluating the efficacy of Treatment A for short-term smoking cessation through a blinded randomized controlled trial (RCT) vs.Treatment B.
- Conditions
- Nicotine Addiction, Drug Addiction, Drug Dependence, Substance Use Disorder
- Trial name
- NCT05440721
- Testing
- Treatment A with device Clickotine® (Active intervention), Treatment B with smoking education (control)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Click Therapeutics, Inc.
Nicotine Addiction
tDCS Effects on Resisting Smoking: Dose Ranging Study
Behaviors such as tobacco use, unhealthy diet, and sedentary behavior have far-reaching health implications. These modifiable behaviors account for a substantial proportion of deaths from cancer, cardiovascular disease and…
- Trial name
- RDR (NCT02624284)
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Substance Dependence
Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809
GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders.
- Trial name
- NCT00437632
- Testing
- GSK598809, Caffeine
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Self-identified Problematic Caffeine Use, DSM-IV Substance Dependence as Applied to Caffeine
Assessment and Treatment of Caffeine Dependence
Recent research has established that some individuals report that they are unable to cease caffeine use, despite feeling that caffeine is posing a health risk or causing significant impairment in their daily activities.
- Trial name
- NCT00338195
- Testing
- Individualized caffeine cessation instructions
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
E-cigarette Use/Vaping Prevention, Nicotine Dependence Prevention
A Virtual Reality E-cigarette Prevention and Emotion Regulation Intervention for Adolescents
This study will examine E-Invite Only VR, a novel school-based universal e-cigarette prevention intervention that uses virtual reality (VR) to deliver prevention and emotion regulation skills-building content to middle school…
- Conditions
- E-cigarette Use/Vaping Prevention, Nicotine Dependence Prevention, Adolescent Mental Health
- Trial name
- NCT07460622
- Testing
- Virtual Reality E-Cigarette Prevention Program
- Where
- United States
- Volunteers
- 1,251 people, healthy volunteers welcome
- Sponsor
- Yale University
Alcohol Addiction, Opiate Addiction
Effectiveness of a Hospital Addiction Service in Treating Opioid and Alcohol Addiction
Hypothesis: Patients who are addicted to opioids or alcohol will have reduced substance use, health care utilization if they have immediate and convenient access to pharmacotherapy and addiction counselling.
- Trial name
- H-SOAP (NCT01934751)
- Testing
- Delayed Intervention (DI), Rapid Intervention (RI)
- Where
- Canada
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Women's College Hospital
Smoking Cessation, Smoking, Cigarette
AXS-05 Phase II Trial on Smoking Behavior
This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.
- Conditions
- Smoking Cessation, Smoking, Cigarette, Nicotine Dependence
- Trial name
- NCT03471767
- Testing
- AXS-05, Bupropion SR
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- James Davis
Access to Primary Care
Access to Primary Care for People With Opioid Use Disorder
Background: Access to high quality primary care is essential for health, particularly for vulnerable populations. Research indicates, however, that people with opioid use disorder (OUD), are less likely than others to have a…
- Trial name
- NCT05484609
- Testing
- OUD scenario, Diabetes scenario
- Where
- Canada
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- Women's College Hospital
Nicotine Dependence
Do Flavors Increase the Addiction Potential of Nicotine?
The FDA has concluded that flavors (e.g. menthol) are associated with greater addiction potential in tobacco cigarettes (Gottlieb March 13, 2019).
- Trial name
- NCT04696380
- Testing
- Nicotine, JUUL e-cigarette
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Opioid Use Disorder, Substance Use Disorders
Strategies to Reduce Addiction Stigma Among Health Professionals
The aim of this study was to evaluate the effects of exposure to stigma reduction message frames communicated by visual campaigns and narrative vignettes among a national sample of health professionals.
- Conditions
- Opioid Use Disorder, Substance Use Disorders, Stigma, Social
- Trial name
- NCT05127707
- Testing
- Words Matter - Visual Campaign, Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician), Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
- Where
- United States
- Volunteers
- 1,842 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections, Opioid-Related Disorders
Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
Drug abuse and HIV/AIDS are serious global health problems. Injection drug use is currently the major mode of transmission of HIV in many countries.
- Trial name
- NCT00270257
- Testing
- Buprenorphine/Naloxone
- Where
- 4 sites in China, Thailand
- Volunteers
- 1,251 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Alcohol Use Disorder
Impulsivity Domains and Subjective Response
Findings from this project will determine the relationship between two vulnerability factors for Alcohol Use Disorder (AUD) in young adults: impulsivity and subjective response to alcohol.
- Trial name
- NCT05929677
- Testing
- Alcohol
- Where
- 2 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Jessica Weafer
Cannabis Dependence
Social and Emotional Brain Function in Cannabis Users
The aim of this functional magnetic resonance imaging (fMRI) study is to find out whether and how social and emotional brain function are altered in dependent cannabis users relative to healthy non-using control subjects after a…
- Trial name
- NCT02711371
- Testing
- fMRI
- Where
- Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Electronic Science and Technology of China
Opioid Abuse and Addiction
Nalmefene Implant in Healthy Subjects
The goal of this clinical trial is to learn how safe either one or two nalmefene implants are after remaining implanted for 4 or 12 weeks.
- Trial name
- NCT07325279
- Testing
- 1 Nalmefene implant, 2 Nalmefene implants
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ReacX Pharmaceuticals, Inc.